Document Detail


Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
MedLine Citation:
PMID:  20678677     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Use of selective cyclooxygenase (COX)-2 inhibitors is associated with a better gastrointestinal (GI) safety profile than use of other NSAIDs. However, the risk factors for clinical upper GI events (symptomatic ulcers and ulcer complications) in COX-2 inhibitor users have been rarely evaluated in the past.
OBJECTIVE: The aim of this study was to assess the annual incidence of and identify the risk factors for clinical upper GI events in chronic COX-2 inhibitor (celecoxib and etoricoxib) users.
METHODS: A prospective, hospital-based, observational cohort study was conducted in patients taking COX-2 inhibitors (celecoxib or etoricoxib) without comorbidity. COX-2 inhibitor prescription was conducted according to the guidelines issued by the Taiwan National Health Insurance and was identified by the computerized prescribing system of the Taipei Veterans General Hospital, Taipei, Taiwan. Patients with cardiovascular disease, pulmonary, hepatic or renal insufficiency, or malignancy were excluded. Patients received regular follow-up once a month. Between visits, patients were asked to report to the outpatient clinic if they had persistent ulcer or GI symptoms (dyspepsia, vomiting, nausea, heartburn, or acid regurgitation) not relieved by antacids for 1 week, or to the emergency department if they had evidence of GI bleeding or ulcer complications (melena, hematemesis, hematochezia, or sudden onset of severe epigastric pain). Endoscopy was performed to document any gastroduodenal ulcers with or without ulcer complications. The primary end point was the annual incidence and the significant risk factors for clinical upper GI events (symptomatic ulcers and ulcer complications).
RESULTS: A total of 1158 COX-2 inhibitor users were identified; 96 refused to participate and 129 were excluded. The mean (SD) age of the remaining 933 COX-2 inhibitor users was 69 (15) years with 528 women (56.6%) and 405 men (43.4%). Mean time of follow-up was 12.4 months. The annual incidence of clinical upper GI events in these patients taking COX-2 inhibitors was 4.6% (44 events/959 patient-years), with symptomatic ulcers in 3.6% and ulcer complications in 1.0%. Multivariate logistic regression analysis found that a history of peptic ulcer disease (PUD) (odds ratio [OR = 4.61; 95% CI, 1.86-11.40; P = 0.001), concomitant use of steroids (OR = 2.99; 95% CI, 1.39-6.46; P = 0.005), aspirin (OR = 13.47; 95% CI, 5.89-30.82; P < 0.001), and other NSAIDs (OR = 60.49; 95% CI, 11.93-306.64; P < 0.001) were significant independent risk factors for clinical upper GI events in these patients taking COX-2 inhibitors. Age >60 years was not found to be a risk factor.
CONCLUSIONS: The annual incidence of clinical upper GI events was 4.6% in these Taiwanese patients without comorbidity taking COX-2 inhibitors. A history of PUD and concomitant use of steroids, aspirin, or other NSAIDs, were found to be significant risk factors for clinical upper GI events in these patients.
Authors:
Kuo-Wei Hsiang; Tseng-Shing Chen; Hsiao-Yi Lin; Jiing-Chyuan Luo; Ching-Liang Lu; Han-Chieh Lin; Kuei-Chuan Lee; Full-Young Chang; Shou-Dong Lee
Related Documents :
3888337 - Surgical treatment of perforated duodenal ulcer: a prospective trial between simple clo...
3887547 - Comparison of ranitidine and high-dose antacid in the treatment of prepyloric or duoden...
15920997 - Treprostinil for the treatment of severe digital necrosis in systemic sclerosis.
8899267 - Trends in contact lens-associated corneal ulcers.
17197307 - Activity level in young patients with primary total hip arthroplasty: a 5-year minimum ...
25354557 - Association between patellar cartilage defects and patellofemoral geometry: a matched-p...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical therapeutics     Volume:  32     ISSN:  1879-114X     ISO Abbreviation:  Clin Ther     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-08-03     Completed Date:  2010-11-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1294-303     Citation Subset:  IM    
Copyright Information:
2010 Excerpta Medica Inc. All rights reserved.
Affiliation:
Department of Medicine, Taipei Veterans General Hospital, Taiwan, R.O.C.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Cohort Studies
Cyclooxygenase 2 Inhibitors / adverse effects*
Female
Follow-Up Studies
Gastrointestinal Diseases / chemically induced*
Humans
Incidence
Logistic Models
Male
Middle Aged
Multivariate Analysis
Peptic Ulcer / complications
Prospective Studies
Pyrazoles / adverse effects*
Pyridines / adverse effects*
Risk Factors
Sulfonamides / adverse effects*
Sulfones / adverse effects*
Taiwan / epidemiology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase 2 Inhibitors; 0/Pyrazoles; 0/Pyridines; 0/Sulfonamides; 0/Sulfones; 169590-42-5/celecoxib; 202409-33-4/etoricoxib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of the implementation of a sepsis protocol for the management of fluid-refractory septic shoc...
Next Document:  A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, piogl...